Cantor Fitzgerald lowered its price target on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) to $3.00 (from $5.00) while maintaining a Neutral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

After-Hours Stock Movers 05/01: (ANGI) (SPAN) (FVE) (AVGO) Higher; (HLIT) (SNSS) (AMD) Lower (more...)May 1, 2017 6:10 PM Sunesis Pharmaceuticals (SNSS) Withdraws EMA MAA for Vosaroxin as Treatment for Relapsed/Refractory AMLMay 1, 2017 4:36 PM Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AMLMay 1, 2017 4:30 PM